Podcast Episodes
Back to SearchExploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL
Episode 211
The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent years, the …
3 years, 1 month ago
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there ha…
3 years, 1 month ago
Pre-MDS states: improving prognosis, novel therapeutic approaches, and challenges with distinguishing these conditions
Episode 210
Myelodysplastic syndromes (MDS) represent a heterogeneic group of disorders which remain a challenge to diagnose and treat. In recent years, there ha…
3 years, 1 month ago
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP)…
3 years, 1 month ago
Accelerated-phase MPNs: mutational landscape, challenges, and novel treatment strategies being explored
Episode 209
Patients with BCR-ABL negative myeloproliferative neoplasms (MPNs) are at risk of progressing to accelerated-phase or blast-phase disease (MPN-AP/BP)…
3 years, 1 month ago
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/ref…
3 years, 2 months ago
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Episode 208
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/ref…
3 years, 2 months ago
Overcoming barriers to CAR-T therapy: improving access and cost
CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several i…
3 years, 2 months ago
Overcoming barriers to CAR-T therapy: improving access and cost
Episode 207
CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several i…
3 years, 2 months ago
The importance of addressing quality of life and improving symptom management in MPNs
Myeloproliferative neoplasms (MPNs) represent a challenging group of diseases to treat, and patients with MPNs suffer from several symptoms which neg…
3 years, 2 months ago